The glioma cell line U251, which develops ALT after ATRX KO [20], was more sensitive to two different ATR inhibitors (AZD6738 and VE-822) in the absence of ATRX, in contrast to the SF188 cell line, which remains ALT-negative (Figure 5). This evidence concerns the gene ATRX and central nervous system cancer.